Osimertinib is a third-generation inhibitor of epidermal growth factor receptor (EGFR), used for treating metastatic, locally advanced, and early-stage non-small-cell lung cancer (NSCLC) with EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.